A Swedish blood test called Stockholm3 identifies roughly 90 percent of aggressive prostate cancers compared to 74 percent caught by traditional PSA screening, according to a major clinical trial published in the Annals of Internal Medicine.
Researchers from the Karolinska Institutet evaluated the new approach in over 12,000 men across Europe, mostly Swedish, ranging in age from 50 to 74. The test achieved superior detection without producing more false alarms than PSA screening.
During the two-year study period, researchers diagnosed 443 men with aggressive prostate cancer. The 16 percentage point gap between the two testing methods translates to patients whose disease might otherwise progress undetected.
The prostate-specific antigen test, the standard screening tool for decades, has limitations. It measures protein levels that can be elevated for reasons beyond cancer, including benign prostate enlargement and infection. The PSA test struggles to distinguish between prostate cancers that threaten life and those that remain dormant for decades without causing harm.
This uncertainty creates consequences. Men with elevated PSA levels face anxiety and additional testing, including MRIs and biopsies—invasive procedures that carry their own risks. Many men end up diagnosed and treated for cancers that would never have threatened their lives, subjecting them to surgery or radiation side effects.
Data from cancer registries show that cases of metastatic prostate cancer have been rising over the past decade, suggesting current screening methods are failing to catch the most dangerous forms while simultaneously overdiagnosing less threatening cancers.
Stockholm3 uses a different approach, measuring multiple biomarkers in blood to create a more sophisticated risk assessment than PSA alone. This allows doctors to better determine which men need further investigation and which can be monitored with less intervention.
When aggressive prostate cancer is caught while confined within the prostate, the five-year survival rate approaches 100 percent.
Stockholm3 is currently investigational and not available for sale in the United States. While the test estimates a man's risk of aggressive prostate cancer with high accuracy, a biopsy remains the definitive method of confirming diagnosis. The manufacturers plan to pursue FDA approval for routine screening use and are working to generate American data that approval would require.
The Swedish cohort in the study, while substantial, may not perfectly represent the genetic diversity of American men. The company's commitment to gathering U.S.-specific data before seeking approval reflects appropriate scientific rigor, as medical breakthroughs must be validated across diverse populations and healthcare systems.
